Biological Asset Securitization Rules.

Biological asset securitization rules

Introduction

Biological asset securitization refers to the process of converting financial interests associated with biological assets into marketable financial instruments. These assets may include agricultural crops, livestock, forestry resources, biological research rights, biotechnology-related receivables and certain contractual interests arising from biological production.

Under this arrangement, an organisation may use expected financial returns from biological assets to support the issuance of securities or other financing instruments. For example, an agricultural enterprise may securitize future receivables generated from livestock production or crop sales to obtain investment capital.

Biological asset securitization combines agricultural finance, biotechnology, property rights, contract law and financial-market regulation. However, biological assets have distinctive characteristics because they may grow, reproduce, deteriorate, become diseased or lose commercial value due to environmental conditions.

India does not have a separate comprehensive statute specifically titled Biological Asset Securitization Rules. Such transactions are governed by existing securities, banking, property, contract, agricultural and environmental laws, depending on their structure.

Legal framework governing biological asset securitization

The Securities Contracts (Regulation) Act, 1956, provides the legal framework for regulating securities contracts and recognised stock exchanges. Where biological asset securitization involves securities or financial instruments falling within the applicable statutory definitions, relevant securities-market requirements must be followed.

The SEBI Act, 1992, empowers the Securities and Exchange Board of India to regulate securities markets and protect investors.

The SEBI (Issue and Listing of Securitised Debt Instruments and Security Receipts) Regulations, 2008, provide a regulatory framework for specified securitised debt instruments and security receipts.

However, these regulations do not automatically cover every financing arrangement involving biological assets. The transaction must satisfy the relevant statutory definitions and eligibility requirements.

The Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 (SARFAESI Act), may also become relevant where eligible financial institutions securitise financial assets or enforce qualifying security interests.

Classification of biological assets

Biological assets may include several categories, each creating different legal and financial considerations.

1. Agricultural biological assets

These include growing crops, plantations and other agricultural resources. Their financial value may depend on harvest quantity, market prices, weather conditions and agricultural productivity.

2. Livestock assets

Animals maintained for agricultural production, breeding or commercial purposes may be considered biological assets in financial reporting. Their valuation may be affected by disease, mortality, reproduction and market demand.

3. Forestry and plantation assets

Timber plantations, forest-based commercial resources and other renewable biological assets may generate future financial returns. Their securitization must account for applicable land, forestry and environmental restrictions.

4. Biotechnology-related assets

These may include qualifying contractual rights, licensing revenues, research-related receivables and other legally transferable financial interests associated with biotechnology operations.

Importantly, biological materials, genetic information and intellectual property are not automatically transferable merely because they have commercial value.

Accounting and valuation requirements

The Companies Act, 2013, establishes financial reporting and accounting obligations for companies.

The Indian Accounting Standards (Ind AS) framework includes Ind AS 41 – Agriculture, which addresses accounting for agricultural activity and biological assets.

Under Ind AS 41, biological assets are generally measured at fair value less costs to sell, subject to specified exceptions.

This accounting treatment is important for securitization because investors and financial institutions require reliable information concerning the value of underlying assets.

Relevant valuation considerations include:

Biological growth and productivity.

Mortality and disease risks.

Environmental and climatic conditions.

Market prices and demand.

Harvesting or production costs.

Legal ownership and transfer restrictions.

Insurance coverage and financial guarantees.

Accounting recognition does not itself establish legal ownership or make an asset eligible for securitization.

Ownership, transfer and security interests

A central legal issue concerns whether the underlying biological asset or associated financial rights can be legally transferred or offered as security.

The Transfer of Property Act, 1882, governs transfers of property interests within its scope. The Indian Contract Act, 1872, provides rules concerning contractual rights, obligations and enforceability.

For movable biological assets, ownership, possession, identification and applicable restrictions must be examined carefully.

The Companies Act, 2013, particularly Section 77, establishes requirements concerning registration of charges created by companies over their property or assets.

Where financing involves a qualifying security interest, applicable registration and enforcement requirements must be satisfied.

Biological assets may also be subject to restrictions arising from agricultural land laws, forest legislation, animal-welfare requirements and biodiversity regulations.

Risk management and investor protection

Biological asset securitization involves risks that may not arise in conventional financial transactions.

Biological risk: Disease, mortality, contamination or reduced productivity may affect the underlying asset.

Environmental risk: Floods, droughts, climate change and other environmental events may reduce asset value.

Valuation risk: Biological assets may be difficult to value because their condition and productivity change over time.

Ownership risk: Disputes may arise concerning title, possession, contractual rights or restrictions on transferring biological resources.

Market risk: Changes in agricultural prices and biotechnology demand may affect expected financial returns.

Securitization documents should therefore clearly disclose the underlying assets, valuation methods, transfer arrangements, financial risks, payment structure and investor rights.

Important judicial decisions

There are no widely recognised Supreme Court judgments in India directly establishing a specialised legal framework for biological asset securitization. However, the following decisions provide relevant principles.

1. Mardia Chemicals Ltd. v. Union of India (2004)

The Supreme Court examined the constitutional validity and operation of the SARFAESI Act. The judgment is relevant to the enforcement of qualifying secured financial interests and the legal framework governing securitisation.

2. Transcore v. Union of India (2008)

The Supreme Court examined the relationship between debt recovery proceedings and enforcement under the SARFAESI Act. Its reasoning is relevant to the enforcement of qualifying security interests created in biological asset financing arrangements.

3. ICICI Bank Ltd. v. SIDCO Leathers Ltd. (2006)

The Supreme Court considered the priority of secured creditors and the legal consequences of competing security interests. This decision is relevant where biological assets are offered as collateral to multiple financial institutions.

4. Central Bank of India v. State of Kerala (2009)

The Supreme Court examined the interaction between secured creditor rights and statutory recovery claims. Its principles are relevant to determining creditor priorities in complex biological asset financing structures.

5. Kailash Nath Associates v. Delhi Development Authority (2015)

The Supreme Court explained the principles governing compensation and reasonable damages under Section 74 of the Indian Contract Act. Its reasoning may be relevant to disputes involving breaches of biological asset financing and securitization agreements.

These decisions concern securitisation, secured lending and contractual enforcement generally. They do not directly decide the securitization of biological assets.

Regulatory challenges and future development

The increasing commercial use of agricultural technology, biotechnology and biological resources may create demand for specialised financing structures.

A more comprehensive regulatory framework could address:

Standardised valuation of biological assets.

Verification of ownership and transferable rights.

Disclosure of biological and environmental risks.

Insurance and risk-sharing requirements.

Creditor priorities and enforcement procedures.

Protection of biodiversity and community interests.

Transparency in securitisation transactions.

Such standards could improve investor confidence while preventing the improper commercial exploitation of biological resources.

Conclusion

Biological asset securitization provides a potential financing mechanism for agricultural enterprises, biotechnology companies and other organisations holding commercially valuable biological assets or related financial rights.

In India, its legal framework is distributed across the SEBI Act, 1992, Securities Contracts (Regulation) Act, 1956, SARFAESI Act, 2002, Transfer of Property Act, 1882, Companies Act, 2013 and applicable accounting standards.

The judgments in Mardia Chemicals, Transcore and ICICI Bank v. SIDCO Leathers provide important principles concerning securitisation, creditor rights and security enforcement.

Ultimately, the legality of biological asset securitization depends on the nature of the asset, ownership rights, transferability, financial structure and applicable regulatory requirements. A dedicated framework could strengthen valuation transparency, investor protection and responsible financing of biological resources.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT